These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The minimum inhibitory concentrations of various bismuth salts against Campylobacter pylori. Vogt K; Warrelmann M; Hahn H Zentralbl Bakteriol; 1989 Sep; 271(3):304-10. PubMed ID: 2803458 [TBL] [Abstract][Full Text] [Related]
5. Colloidal bismuth subcitrate (DE-NOL) and tinidazole healed duodenal ulceration with a low relapse rate due to elimination of Campylobacter pylori. Goodwin CS; Marshall BJ; Blackbourn SJ; Warren JR; Phillips M J Chemother; 1989 Jul; 1(4 Suppl):838-9. PubMed ID: 16312662 [No Abstract] [Full Text] [Related]
6. Eradication of Campylobacter pylori and recurrence of duodenal ulcer. A six-month follow-up study. Mouzas IA; Kalantzis N; Gabriel P; Kallimanis G; Papantoniou P; Mavrogiannis H Acta Gastroenterol Latinoam; 1990; 20(3):159-61. PubMed ID: 2095099 [TBL] [Abstract][Full Text] [Related]
7. [Comparison of colloidal bismuth subcitrate with ranitidine in healing and relapse of Campylobacter pylori-associated duodenal ulcers]. Hu FL; Jia BQ; Gao HZ Zhonghua Nei Ke Za Zhi; 1990 Jun; 29(6):339-41, 382. PubMed ID: 2269032 [TBL] [Abstract][Full Text] [Related]
8. [Effect of bismuth subsalicylate versus cimetidine on Campylobacter pylori, ulcer healing and rate of recurrence]. Eberhardt R; Kasper G; Dettmer A; Höchter W; Hagena D Med Klin (Munich); 1988 May; 83(12):402-5. PubMed ID: 3043160 [No Abstract] [Full Text] [Related]
9. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Wagstaff AJ; Benfield P; Monk JP Drugs; 1988 Aug; 36(2):132-57. PubMed ID: 3053124 [TBL] [Abstract][Full Text] [Related]
11. Recent experimental and clinical studies on the pharmacology of colloidal bismuth subcitrate. Elder JB Scand J Gastroenterol Suppl; 1986; 122():14-6. PubMed ID: 3535016 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. Park KN; Hahm JS; Kim HJ Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924 [TBL] [Abstract][Full Text] [Related]
13. Campylobacter pylori infection in uremic dialyzed patients. Eradication of the infection by colloidal bismuth subcitrate. Conz P; Feriani M; Milan M; Bernardini D; Crepaldi C; La Greca G Nephron; 1990; 55(4):442-3. PubMed ID: 2392203 [No Abstract] [Full Text] [Related]
14. [Effects of colloidal bismuth subcitrate and aluminum hydroxide on gastric and duodenal levels of prostaglandin E2]. Estela R; Feller A; Backhouse C; Castro R; Ugarte G Rev Med Chil; 1984 Oct; 112(10):975-81. PubMed ID: 6399150 [No Abstract] [Full Text] [Related]
15. Colloidal bismuth subcitrate in peptic ulcer disease. Tytgat GN S Afr Med J; 1986 Jul; 70(1):31-3. PubMed ID: 3523793 [TBL] [Abstract][Full Text] [Related]
17. [Therapy of peptic ulcer and chronic gastritis with bismuth salts]. Rösch W Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149 [TBL] [Abstract][Full Text] [Related]
18. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Bianchi Porro G; Parente F; Lazzaroni M Gut; 1993 Apr; 34(4):466-9. PubMed ID: 8491391 [TBL] [Abstract][Full Text] [Related]
19. Colloidal bismuth subcitrate tablets and placebo in chronic duodenal ulceration: a double-blind, randomised trial. Wilson P; Alp MH Med J Aust; 1982 Mar; 1(5):222-3. PubMed ID: 7045603 [TBL] [Abstract][Full Text] [Related]
20. The potential impact of Campylobacter pylori on the treatment of duodenal ulcer disease. Miller JP; Faragher EB Scand J Gastroenterol Suppl; 1989; 160():39-45. PubMed ID: 2573145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]